325 related articles for article (PubMed ID: 32715723)
1. New Therapeutic Targets and Treatment Options for Thrombotic Microangiopathy: Caplacizumab and Ravulizumab.
Chung C
Ann Pharmacother; 2021 Mar; 55(3):330-343. PubMed ID: 32715723
[TBL] [Abstract][Full Text] [Related]
2. A critical evaluation of caplacizumab for the treatment of acquired thrombotic thrombocytopenic purpura.
Gómez-Seguí I; Fernández-Zarzoso M; de la Rubia J
Expert Rev Hematol; 2020 Nov; 13(11):1153-1164. PubMed ID: 32876503
[No Abstract] [Full Text] [Related]
3. Caplacizumab reduces the frequency of major thromboembolic events, exacerbations and death in patients with acquired thrombotic thrombocytopenic purpura.
Peyvandi F; Scully M; Kremer Hovinga JA; Knöbl P; Cataland S; De Beuf K; Callewaert F; De Winter H; Zeldin RK
J Thromb Haemost; 2017 Jul; 15(7):1448-1452. PubMed ID: 28445600
[TBL] [Abstract][Full Text] [Related]
4. Caplacizumab: an anti-von Willebrand factor antibody for the treatment of thrombotic thrombocytopenic purpura.
Hollifield AL; Arnall JR; Moore DC
Am J Health Syst Pharm; 2020 Jul; 77(15):1201-1207. PubMed ID: 32588878
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of open-label caplacizumab in patients with exacerbations of acquired thrombotic thrombocytopenic purpura in the HERCULES study.
Knoebl P; Cataland S; Peyvandi F; Coppo P; Scully M; Kremer Hovinga JA; Metjian A; de la Rubia J; Pavenski K; Minkue Mi Edou J; De Winter H; Callewaert F
J Thromb Haemost; 2020 Feb; 18(2):479-484. PubMed ID: 31691462
[TBL] [Abstract][Full Text] [Related]
6. Caplacizumab as an emerging treatment option for acquired thrombotic thrombocytopenic purpura.
Elverdi T; Eskazan AE
Drug Des Devel Ther; 2019; 13():1251-1258. PubMed ID: 31118566
[TBL] [Abstract][Full Text] [Related]
7. Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura.
Scully M; Cataland SR; Peyvandi F; Coppo P; Knöbl P; Kremer Hovinga JA; Metjian A; de la Rubia J; Pavenski K; Callewaert F; Biswas D; De Winter H; Zeldin RK;
N Engl J Med; 2019 Jan; 380(4):335-346. PubMed ID: 30625070
[TBL] [Abstract][Full Text] [Related]
8. Clinical pharmacology of caplacizumab for the treatment of patients with acquired thrombotic thrombocytopenic purpura.
Sargentini-Maier ML; De Decker P; Tersteeg C; Canvin J; Callewaert F; De Winter H
Expert Rev Clin Pharmacol; 2019 Jun; 12(6):537-545. PubMed ID: 30977686
[No Abstract] [Full Text] [Related]
9. Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura.
Peyvandi F; Scully M; Kremer Hovinga JA; Cataland S; Knöbl P; Wu H; Artoni A; Westwood JP; Mansouri Taleghani M; Jilma B; Callewaert F; Ulrichts H; Duby C; Tersago D;
N Engl J Med; 2016 Feb; 374(6):511-22. PubMed ID: 26863353
[TBL] [Abstract][Full Text] [Related]
10. Successful use of caplacizumab in a case of refractory acquired thrombotic thrombocytopenic purpura following subacute thyroiditis.
Loscocco GG; Malandrino D; Vannini F; Vinci MC; Di Marzio G; Fallai L; Scappini B
Transfus Apher Sci; 2021 Feb; 60(1):103010. PubMed ID: 33223471
[TBL] [Abstract][Full Text] [Related]
11. Cost effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura.
Goshua G; Sinha P; Hendrickson JE; Tormey C; Bendapudi PK; Lee AI
Blood; 2021 Feb; 137(7):969-976. PubMed ID: 33280030
[TBL] [Abstract][Full Text] [Related]
12. Caplacizumab for relapsing thrombotic thrombocytopenic purpura.
Kaczmarek V; Holle J; Astudillo R; Kempf C; Bufler P; Müller D
Pediatr Nephrol; 2019 Sep; 34(9):1625-1628. PubMed ID: 31177334
[TBL] [Abstract][Full Text] [Related]
13. The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment.
Rondeau E; Scully M; Ariceta G; Barbour T; Cataland S; Heyne N; Miyakawa Y; Ortiz S; Swenson E; Vallee M; Yoon SS; Kavanagh D; Haller H;
Kidney Int; 2020 Jun; 97(6):1287-1296. PubMed ID: 32299680
[TBL] [Abstract][Full Text] [Related]
14. Treatment of acquired thrombotic thrombocytopenic purpura without plasma exchange in selected patients under caplacizumab.
Völker LA; Brinkkoetter PT; Knöbl PN; Krstic M; Kaufeld J; Menne J; Buxhofer-Ausch V; Miesbach W
J Thromb Haemost; 2020 Nov; 18(11):3061-3066. PubMed ID: 32757435
[TBL] [Abstract][Full Text] [Related]
15. The long-acting C5 inhibitor, ravulizumab, is effective and safe in pediatric patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment.
Ariceta G; Dixon BP; Kim SH; Kapur G; Mauch T; Ortiz S; Vallee M; Denker AE; Kang HG; Greenbaum LA;
Kidney Int; 2021 Jul; 100(1):225-237. PubMed ID: 33307104
[TBL] [Abstract][Full Text] [Related]
16. When to consider targeted therapies in thrombotic microangiopathies in the modern era: walking the tightrope between cost, safety, and efficacy.
Murphree CR; Olson SR; DeLoughery TG; Shatzel JJ
J Thromb Thrombolysis; 2020 May; 49(4):602-605. PubMed ID: 32219721
[TBL] [Abstract][Full Text] [Related]
17. Caplacizumab to treat immune-mediated thrombotic thrombocytopenic purpura.
Poullin P; Bornet C; Veyradier A; Coppo P
Drugs Today (Barc); 2019 Jun; 55(6):367-376. PubMed ID: 31250841
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of the long-acting C5 inhibitor ravulizumab in patients with atypical hemolytic uremic syndrome triggered by pregnancy: a subgroup analysis.
Gäckler A; Schönermarck U; Dobronravov V; La Manna G; Denker A; Liu P; Vinogradova M; Yoon SS; Praga M
BMC Nephrol; 2021 Jan; 22(1):5. PubMed ID: 33407224
[TBL] [Abstract][Full Text] [Related]
19. Caplacizumab Model-Based Dosing Recommendations in Pediatric Patients With Acquired Thrombotic Thrombocytopenic Purpura.
Bergstrand M; Hansson E; Delaey B; Callewaert F; De Passos Sousa R; Sargentini-Maier ML
J Clin Pharmacol; 2022 Mar; 62(3):409-421. PubMed ID: 34699078
[TBL] [Abstract][Full Text] [Related]
20. Should all patients with immune-mediated thrombotic thrombocytopenic purpura receive caplacizumab?
Picod A; Veyradier A; Coppo P
J Thromb Haemost; 2021 Jan; 19(1):58-67. PubMed ID: 33236389
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
